Scholarlink

<p>Vitiligo is an autoimmune cutaneous disease characterized by focal or generalized depigmentation due to loss of melanocytes. As more molecularly targeted therapies gain FDA approval or achieve positive late-stage clinical trials results, an opportunity exists to summarize the current state of the art in vitiligo biomarker and omics studies. Vitiligo is an unpredictable disease, with the clinical course varying from patient to patient. Leveraging the wide range of available multi-omic data may help identify biomarkers that can assist with prognostication (e.g., active vs. stable disease) and treatment selection. This review aims to summarize the literature on non-segmental vitiligo molecular biology, including genetics, transcriptomics, miRNA biology, proteomics, lipidomics, and metabolomics, with an eye towards identifying potential candidate biomarkers for future clinical development. Utilizing an evidence rating tool for critical appraisal of selected biomarkers, several candidate biomarkers are highlighted for their association with disease activity or treatment response, including serum measurements of CXCL10, CXCL9, IL-17, miR-25, IFN- γ, IL-6, and MIF.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disease activity and treatment response biomarkers in vitiligo: a scoping review of multi-omic studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月4日

查看全文
  • Aileen Y. Hu,
  • Nabor Mireles,
  • Vicky Ren,
  • Vikram R. Shaw

摘要

Vitiligo is an autoimmune cutaneous disease characterized by focal or generalized depigmentation due to loss of melanocytes. As more molecularly targeted therapies gain FDA approval or achieve positive late-stage clinical trials results, an opportunity exists to summarize the current state of the art in vitiligo biomarker and omics studies. Vitiligo is an unpredictable disease, with the clinical course varying from patient to patient. Leveraging the wide range of available multi-omic data may help identify biomarkers that can assist with prognostication (e.g., active vs. stable disease) and treatment selection. This review aims to summarize the literature on non-segmental vitiligo molecular biology, including genetics, transcriptomics, miRNA biology, proteomics, lipidomics, and metabolomics, with an eye towards identifying potential candidate biomarkers for future clinical development. Utilizing an evidence rating tool for critical appraisal of selected biomarkers, several candidate biomarkers are highlighted for their association with disease activity or treatment response, including serum measurements of CXCL10, CXCL9, IL-17, miR-25, IFN- γ, IL-6, and MIF.